NCT03564821View on ClinicalTrials.gov

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

May 22, 2022

Study Completion Date

June 6, 2023

Conditions
IDH1 Mutation Myeloid Neoplasms
Interventions
DRUG

Ivosidenib

Ivosidenib is an inhibitor of the protein IDH1

Trial Locations (4)

21218

Johns Hopkins Cancer Center, Baltimore

43210

Ohio State University Comprehensive Cancer Center, Columbus

02115

Dana Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Agios Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER